JCB, Volume 19, Number 2, 2013 Commentary Vol.19 No. 2 (2013) Capturing Value G. Steven Burrill Today’s pressure on pharmaceutical companies reflects greater pressures throughout the entire healthcare ecosystem as payers, patients, and providers wrestle with escalating costs Commentary Vol.19 No. 2 (2013) Defining valuable information in a shifting industry Andrew F Bourgoin Commentary Vol.19 No. 2 (2013) Commercial Biotechnology in Mexico Minerva Valdes Article Vol.19 No. 2 (2013) Technology Transfer: Bridging academic research and society – a communicative approach Martin Vad Bennetzen To make basic research transcend the walls of a university for the benefit of the society, technology transfer processes such as patenting, market analysis, and economic assessment are es Article Vol.19 No. 2 (2013) The financial ecosystem available to early-stage biotechnology firms and its misalignment with interests of these firms, of the biotechnology industry and with global disease burden Gergely Toth The development and commercialization of new therapeutics have had immense impact on the quality and length of human life. Nevertheless, the biotechnology and the pharmaceutical indus Article Vol.19 No. 2 (2013) A Patient Centric Commercial Model for Cancer Care Sanjay Rao Cancer is one of the most challenging diseases of all - not only in terms of the clinical barriers to offering its sufferers respite from devastating consequences, but also to manufacture Article Vol.19 No. 2 (2013) Developing Cell Therapies: Enabling cost prediction by value systems modeling to manage developmental risk. Mark Joseph McCall This work quantifies the highest risk activities and interdependencies in cell therapy new product development (NPD). A simulation model based upon an activates based and information Article Vol.19 No. 2 (2013) Challenges and prospects for monoclonal antibodies in China Honghao Shi The technology of monoclonal antibodies has been developed since the 1990s and is attracting more and more attention in China during the 21st century. The first monoclonal antibody produc From the Boardroom Vol.19 No. 2 (2013) A Business Perspective on IP: Open Innovation vs. Open Source in Commercializing Biotechnology Arthur A. Boni Abstract – In this article, we address the issues that are involved when developing a strategy for commercializing a discovery that is novel, useful, and non-obvio From the Boardroom Vol.19 No. 2 (2013) Getting Social with Biotechnology Business Development Tim McCready Social media is becoming increasingly important in business. While the lack of regulations makes marketing online to consumers a challenge in the life sciences, social media offers signif Legal and Regulatory Updates Vol.19 No. 2 (2013) Bowman v. Monsanto: Revisiting the Exhaustion Doctrine and its Application to Biotechnology and Digital Technologies Susan Kling Finston On February 19, 2013, the U.S. Supreme Court heard oral argument in Bowman v. Monsanto – the first case to directly present the question of how the Exhaustion Doctrine should apply to Legal and Regulatory Updates Vol.19 No. 2 (2013) Should the HHS Decision to Overrule FDA on Plan B Be Reversed Peter J. Pitts On December 7, 2011, Secretary of Health and Human Services Kathleen Sebelius overruled a decision of the Food and Drug Administration (FDA) on the over-the-counter (OTC) status of emerge
